title: Effect of R-CHOP chemotherapy on liver and mediastinal blood pool (18)F-FDG standardized uptake values in patients with non-Hodgkin's lymphoma.
abstract: OBJECTIVE
  We aimed to investigate the impact of chemotherapy on (18)F-FDG uptake in the liver and mediastinal blood pool (MBP) among patients with non-Hodgkin's lymphoma.
  
  
  METHODS
  Twenty-three patients with NHL underwent baseline, interim, and postchemotherapy (18)F-FDG PET/CT. SUVmax and SUVmean values of the liver and MBP at imaging time were compared statistically.
  
  
  RESULTS
  We did not find any significant differences between the liver and mediastinum SUVmean and SUVmax values (P>.05).
  
  
  CONCLUSIONS
  Our study demonstrates that the (18)F-FDG uptake in the liver and MBP are not significantly affected by R-CHOP chemotherapy in patients with NHL.
authors.affiliation: Necmettin Erbakan University, Meram Medical Faculty, Department of Nuclear Medicine, Konya, Turkey. Electronic address: bugrakaya01@gmail.com.
authors.forename: Bugra
authors.initials: B
authors.lastname: Kaya
authors.affiliation: Dicle University, Medical Faculty, Department of Nuclear Medicine, Diyarbakir, Turkey. Electronic address: zekidostbil@yahoo.com.
authors.forename: Zeki
authors.initials: Z
authors.lastname: Dostbil
authors.affiliation: Dr. I. Sevki Atasagun Nevsehir State Hospital, Department of Nuclear Medicine, Nevsehir, Turkey. Electronic address: mismailoglu2003@yahoo.com.
authors.forename: Murat
authors.initials: M
authors.lastname: Ismailoglu
authors.affiliation: Dicle University, Medical Faculty, Department of Nuclear Medicine, Diyarbakir, Turkey. Electronic address: drbkr@hotmail.com.
authors.forename: Bekir
authors.initials: B
authors.lastname: Tasdemir
authors.affiliation: Afyonkarahisar State Hospital, Department of Nuclear Medicine, Afyonkarahisar, Turkey. Electronic address: drozlemsahin@hotmail.com.
authors.forename: Ozlem
authors.initials: O
authors.lastname: Sahin
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008099:Liver / Q000000981:diagnostic imaging* / Q000187:drug effects; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008297:Male; D008482:Mediastinum / Q000000981:diagnostic imaging*; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use; D019275:Radiopharmaceuticals; D000069283:Rituximab; D014750:Vincristine / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Chemotherapy; Non-Hodgkin’s lymphoma; PET; R-CHOP; Standardized uptake value